To the full analysis
Buyback calculator for Shenzhen Salubris Pharmaceuticals
Shenzhen Salubris Pharmaceuticals stock: key metrics
002294.SZShenzhen Salubris Pharmaceuticals had an operating margin of 14.6% and a return on invested capital (ROIC) of 9% in fiscal 2025.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2006 | 47.3% | 18.4% | 16.9% |
| 2007 | 46.8% | 21.8% | 20.9% |
| 2008 | 50.8% | 23.9% | 22.2% |
| 2009 | 55.7% | 28.9% | 25.4% |
| 2010 | 57.2% | 30.2% | 27.4% |
| 2011 | 62.0% | 30.4% | 27.5% |
| 2012 | 74.5% | 38.9% | 34.7% |
| 2013 | 75.7% | 41.6% | 35.7% |
| 2014 | 73.5% | 41.9% | 36.2% |
| 2015 | 73.8% | 42.5% | 36.4% |
| 2016 | 75.2% | 42.5% | 36.4% |
| 2017 | 81.1% | 41.3% | 35.0% |
| 2018 | 79.7% | 37.0% | 31.3% |
| 2019 | 78.4% | 18.9% | 16.0% |
| 2020 | 69.0% | 2.9% | 2.2% |
| 2021 | 73.5% | 19.2% | 17.5% |
| 2022 | 71.3% | 20.9% | 18.3% |
| 2023 | 68.3% | 19.5% | 17.2% |
| 2024 | 71.6% | 16.1% | 15.0% |
| 2025 | 72.7% | 14.6% | 15.1% |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2006 | 32.2% | 30.7% | 21.6% |
| 2007 | 50.1% | 56.1% | 28.6% |
| 2008 | 44.5% | 55.4% | 28.6% |
| 2009 | 13.3% | 57.9% | 12.2% |
| 2010 | 19.1% | 50.9% | 16.3% |
| 2011 | 19.0% | 36.4% | 16.6% |
| 2012 | 24.4% | 41.6% | 21.3% |
| 2013 | 26.5% | 42.5% | 22.8% |
| 2014 | 27.6% | 41.7% | 22.6% |
| 2015 | 27.6% | 39.0% | 23.5% |
| 2016 | 26.1% | 36.8% | 21.4% |
| 2017 | 24.0% | 34.8% | 21.2% |
| 2018 | 21.9% | 28.3% | 18.5% |
| 2019 | 11.0% | 11.8% | 9.2% |
| 2020 | 1.1% | 1.3% | 0.9% |
| 2021 | 6.6% | 10.6% | 5.8% |
| 2022 | 8.0% | 12.9% | 6.5% |
| 2023 | 7.2% | 10.1% | 6.2% |
| 2024 | 6.9% | 9.1% | 5.7% |
| 2025 | 7.3% | 9.0% | 5.8% |
Data status and sources
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = CN¥6.6683)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 31 Jul 2024)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.